导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 4.47% | 494/1840 |
| 近一周 | -1.92% | 1087/2029 |
| 近一月 | -3.00% | 782/2018 |
| 近一季 | -4.42% | 718/1966 |
| 近半年 | 2.25% | 402/1877 |
| 近一年 | 10.17% | 411/1753 |
| 近两年 | 57.04% | 531/1324 |
| 近三年 | 25.72% | 521/1010 |
| 成立以来 | 55.33% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.30% 2751/4961 |
13.81% 1936/5312 |
- - |
- - |
| 2025 | 28.19% 1503/4813 |
-0.12% 2071/3635 |
4.88% 689/4076 |
19.06% 2194/4524 |
2.78% 854/4813 |
| 2024 | 1.96% 1987/3463 |
-3.36% 1494/2808 |
-2.45% 1191/3014 |
12.65% 2305/3129 |
-3.98% 2413/3463 |
| 2023 | -13.75% 1557/2656 |
0.11% 1762/2280 |
-5.44% 1457/2385 |
-0.66% 432/2515 |
-8.28% 2274/2655 |
| 2022 | -21.84% 1054/2207 |
-13.02% 686/1919 |
5.94% 808/2016 |
-12.39% 700/2113 |
-3.18% 1840/2208 |
| 2021 | -1.93% 828/1822 |
-2.00% 569/1255 |
5.95% 780/1330 |
-5.80% 861/1466 |
0.27% 1145/1822 |
| 2020 | 32.85% 472/1250 |
-7.60% 555/1028 |
13.54% 611/1067 |
12.79% 362/1164 |
12.27% 485/1184 |
| 2019 | - - |
- - |
2.08% 101/804 |
2.64% 293/850 |
7.02% 503/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 长城久泰沪深300指数C VS. 长安沪深300非周期A(740101) |